Risk factors for peritonitis, the prevention of peritonitis, the need for epidemiologic studies, key issues when developing an empirical antibiotic therapy strategy.

Volume status in PD, importance of residual renal function, evaluation methods of volume status, how to achieve euvolemia.

Strategies to enhance the numbers of incident patients starting on PD and strategies to improve technique success

Opening of the Exhibition, Posters and 10th EuroPD Welcome Reception

Chairs: G Gahl, Berlin, Germany & C Verger, Pontoise, France

What is the underlying patho-physiology of malnutrition and anabolism/catabolism?  Which patho-physiological factors drive/inhibit a good nutritional state in ESRD and PD?

How can we evaluate nutritional status on a clinical basis, and is this relevant? SGA, waist, waist to hip, BMI, callipers, handgrip strength.

Use of DEXA, MR, bio-impedance etc, and use of biochemical tools.

What is the nutritional status in PD? What are the causes? Inflammation? Deficient Caloric and/or protein intake? And how can we improve it? Exercise? Anabolic steroids? Dietary advice? Hyperalimentation?

A selection of the best posters will be discussed in a walking tour of the poster area and will be conducted by:

Cardiovascular
P4 - P10
C  Tomson, London, UK, B Lindholm, Stockholm, Sweden

Clinical PD

P28 - P39: P41 - P68: P88, P129
M Dratwa, Brussels, Belgium; B Bammens, Leuven, Belgium    

Paediatrics 
P24 - P27

J van der Voort, Cardiff, UK,

ANIMOD
P1 - P3
P Ter Wee, Amsterdam, The Netherlands; J Witowski, Poznan, Poland

Dialysis Solutions 
P11 - P23
P Ter Wee, Amsterdam, The Netherlands; J Witowski, Poznan, Poland

Euvolemia In PD Patients
Chair: S Davies, Stoke on Trent, UK

Sodium is one of the forgotten uremic toxins, not only because of volume aspects, but also for its pleiotropic effects: the salt in the wound

What are the pathways of fluid flux across the peritoneal membrane? How do they vary between individuals ad with  time on treatment?  Do we use dialysis with the optimal sodium concentration?

How can we evaluate hydration status (and what do we mean by it) in patients in 2011?

It is a well established urban myth that hydration status in PD is worse than in HD. But is this really the case? And what does it mean?

Innovating in PD -  A Multidisciplinary Business (Chairs: E Brown & J Macdonald)

Home Hemodialysis

Chairs: W van Biesen, Ghent, Belgium & S Mitra, Manchester, UK 

Both therapies being “home therapies” there is the risk for cannibalism, but is this really happening in practice? Why invest in individual treatment units if we have satellite units? Do we need alternative dialysis strategies? What are the differences in patient phenotype?

What are the outcomes of homeHD in comparison to HD, PD etc

How do we start/run/maintain a home HD program?

In the perspective of society and even the individual, it might be preferable to promote home HD rather than transplantation for “middle aged” CKD patients?

Chair: J Witowski, Poznan, Poland

Each presenter will give data and conclusions, and further interpretation/background of the most relevant PD related papers of the last year  

Peter Margetts¹, Limin Liu¹, Ron Korstanje², Louise Walkin³, Angela Summers³, Sarah Herrick³, Paul Brenchley³, Catherine Hoff⁴

¹McMaster University, Hamilton, Ontario, Canada, ²The Jackson Laboratory, Bar Harbor, ME, USA, ³University of Manchester, Manchester, United Kingdom, ⁴Baxter Healthcare Corporation, McGaw Park, IL, USA

Peter Margetts¹, Limin Liu¹, Ron Korstanje², Catherine Hoff³, Louise Walkin⁴, Angela Summers⁴, Sarah Herrick⁴, Paul Brenchley⁴

¹McMaster University, Hamilton, Ontario, Canada, ²The Jackson Laboratory, Bar Harbor, ME, USA, ³Baxter Healthcare Corporation, McGaw Park, IL, USA, ⁴University of Manchester, UK

Samir Osta¹, Dina Abdellatif¹, Mark Lambie², Simon Davis², Nicholas Topley³, Angela Summers⁴, Paul Brenchley⁴, Linghong Huang¹, Martin Wilkie¹, Tim Johnson¹

¹Sheffield Kidney Institute, Sheffield, UK, ²Department of Nephrology, University Hospital of North Staffordshire, Stoke on Trent, UK, ³Medical Biochemistry and Immunology, Cardiff University,  UK, ⁴Manchester Royal Infirmary, UK

Anneleen Pletinck¹, Griet Glorieux¹, Eva Schepers¹, Maria Van Landschoot¹, Johan Van de Voorde², Wim Van Biesen¹, Raymond Vanholder¹

¹Department of Nephrology, Ghent University, Ghent, Belgium, ²Department of Pharmacology, Ghent University, Ghent, Belgium

Klaus Kratochwill¹, Rebecca Herzog³, Anton Lichtenauer¹, Michael Boehm¹, Hans Lederhuber¹, Michael Lechner², Elisabeth Salzer¹, Paul Perco⁴, Bernd Mayer⁴, Andreas Rizzi², Christoph Aufricht¹

¹Medical University of Vienna, Austria, ²University of Vienna, Austria, ³Zytoprotec GmbH, Vienna, Austria, ⁴Emergentec Biodevelopment GmbH, Vienna, Austria

Betti Schaefer¹, Stephan Goeppinger², Sandra Weih³, Bärbel Philippin¹, Christa Flechtenmacher², Vedat Schwenger⁴, Franz Schaefer¹, Stephan Holland-Cunz³, Claus Peter Schmitt¹

¹Center for Pediatric and Adolescent Medicine, University of Heidelberg,  Germany, ²Department of Pathology, University of Heidelberg, Germany, ³Division of Pediatric Surgery, University of Heidelberg, Germany, ⁴Department of Nephrology, University of Heidelberg, Germany

Magda Galach¹, Daniel Baczynski², Stefan Antosiewicz², Zofia Wankowicz², Jacek Waniewski¹

¹Nalecz Institute of Biocybernetics and Biomedical Engineering, Polish Academy of Sciences, Warsaw, Poland, ²Department of Internal Medicine, Nephrology and Dialysotherapy, Military Institute of Medicine, Warsaw, Poland

Chan-Yu Lin¹, Gareth W. Roberts², Martin S. Davey¹, James A. Chess³, John D. Williams², Simon J. Davies⁴, David W. Johnson⁵, Bernhard Moser¹, Nicholas Topley¹, Matthias Eberl¹

¹Department of Infection, Immunity and Biochemistry, Cardiff University, UK, ²Institute of Nephrology, School of Medicine, Cardiff University, UK, ³Department of Nephrology, Morriston Hospital, Swansea, United Kingdom, ⁴Department of Nephrology, University Hospital of North Staffordshire, Keele University, Stoke-on-Trent, United Kingdom, ⁵Australia and New Zealand Dialysis Transplant Registry, University of Adelaide, Australia

Bruce Riser¹, Fellype Barreto², Paul Valaitis¹, Tilman Drueke², Zaid Massy²

¹Renal Division, Baxter Healthcare Corp, McGaw Park, Illinois, USA, ²ERI-12 (EA4292), INSERM, Amiens, France

Zanzhe Yu¹, Boon Kay Tan¹, Derek L Mattey², Stephen Dainty³, Simon J Davies¹

¹Department of Nephrology, University Hospital of North Staffordshire, Stoke on Trent, UK,  ²Staffordshire Rheumatology Center, Haywood Hospital, Stoke on Trent, UK, ³Department of Nuclear Medicine University Hospital of North Staffordshire, Stoke on Trent, UK

Magda Galach¹, Edward Vonesh², Alp Akonur³, Jacek Waniewski¹

¹Nalecz Institute of Biocybernetics and Biomedical Engineering, Polish Academy of Sciences, Warsaw, Poland, ²Department of Preventive Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Il, USA, ³Renal, Baxter Healthcare Corporation, Mcgaw Park, Il, USA

Boon Kay Tan¹, Zanzhe Yu¹, Frauke Wenzelburger¹, Hayley King¹, Sarah Jenkins², Martin Wilkie², Graham Woodrow³, John Sanderson¹, Simon J Davies¹

¹Nephrology Department, University Hospital of North Staffordshire & Keele University, Stoke on Trent, UK, ²Sheffield Kidney Institute, Northern General Hospital, Sheffield, UK, ³Renal Department, St James's University Hospital NHS Trust, Leeds, UK

Basic Science 2  

“Omics”: The Systems Biology Approach to PD

Chairs: N Topley, Cardiff, UK & J Witowski, Poznan, Poland 

Increasing PD Utilisation